Your Trusted Brand for Over 35 Years

Inflammatory Bowel Disease (Crohn’s and Ulcerative Colitis) References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011;106:731-6.
  2. Cosnes J. Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies? Dig Dis 2009;27:516-21.
  3. Rutgeerts P, Löfberg R, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–5.
  4. Ruffolo C et al. Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire. J Gastrointest Surg. 2010 Jan;14(1):24-31. Epub 2009 Nov 10.
  5. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57(11):1518-23.
  6. Abraham C and Cho JH. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19;361(21):2066-78.
  7. Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol. 2004 Dec;13(4):309-16.
  8. Sato S, Sasaki I, et al. Management of urinary complications in Crohn's disease. Surg Today. 1999;29(8):713-7.
  9. Feller ER, Ribaudo S, et al. Gynecologic aspects of Crohn's disease. Am Fam Physician. 2001 Nov 15;64(10):1725-8.
  10. Tavarela VF. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct;20(suppl 4):50-3.
  11. Vermeire S, Peeters M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7(1):8-15.
  12. Tursi A et al. h prevalence of celiac disease among patients affected by Crohn's disease. Inflamm Bowel Dis. 2005 Jul;11(7):662-6.
  13. Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther. 2004 Jul 15;20(2):151-9.
  14. Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs. 2002;62(11):1689-705.
  15. 15, Jansen G et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications ofr combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 2004 Jul;50(7):2130-9
  16. Krasinski SD, Russell RM et al. The prevalence of vitamin K deficiency in chronic gastrointestinal disorders. Am J Clin Nutr 1985;41(3):639-43.
  17. Homik J, Suarez-Almazor ME, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;(2):CD000952.
  18. Newman WG et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011 Jun;12(6):815-26. Epub 2011 May 3.
  19. Preiss JC et al. Use of methotrexate in patients with inflammatory bowel disease. Clin Exp Rheumatol. 2010 Sep-Oct;28 (5 Suppl 61):S151-5
  20. Xu CT, Meng SY et al. Drug therapy for ulcerative colitis. World J Gastroenterol. 2004 Aug 15;10(16):2311-7.
  21. Patel V, Macdonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009 Oct 7;(4):CD006884.
  22. Coogan PF, Rosenberg L. The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 2007;16(10):1111-9.
  23. Malik T, Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci 2012;S4:1172-89.
  24. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database System Rev 2008;(1):CD006893.
  25. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2006;25:19-37.
  26. Aratari A, Papi C, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liv Dis 2008;40:821-6.
  27. Colombel JF, Loftus EV Jr, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126;19-31.
  28. Malolepszy J, Kuczymska-Sekieta K, Chachaj W. Sodium cromoglycate therapy in ulcerative colitis. Acta Allergol 1977;13:82–86.
  29. Stefanini GF et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol. 1995 Jun;30(6):535-41.
  30. Smith JP, Bingaman SI, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci 201156:2088-97.
  31. Smith JP, Stock H, Bingaman S, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol 2007;102:820-8.
  32. Matters GL et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008 Apr;5(2):179-87.
  33. Braunwald E. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
  34. McNamara DA, Brophy S, Hyland JM. Perianal Crohn’s disease and infliximab therapy. Surgeon. 2004 Oct;2(5):258-63.
  35. Danelli P, Bartolucci C, et al. Surgical options in the treatment of perianal Crohn's disease [in Italian]. Ann Ital Chir. 2003 Nov;74(6):635-40.
  36. Hwang JM et al. Surgery for inflammatory bowel disease. World J Gastroenterol. 2008 May 7;14(17):2678-90.
  37. Yamamoto T, Nakahigashi M, et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: A prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther 2007;25:67-72.
  38. Esaki M, Matsumoto T, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand J Gastroenterol 2005;40:1431-7.
  39. Elahi B, Nikfar S, et al. On the benefit of probiotics in the management of pouchitis in patients that underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53(5):1278-84.
  40. Chan SSM, Luben R, et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther 2011;34:649-55.
  41. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005;21:921–31.
  42. Riordan AM, Hunter JO, et al. Treatment of active Crohn's disease by exclusion diet: East Anglian Multicentre Controlled Trial. Lancet 1993;342:1131-4.
  43. Bartel G, Weiss I, et al. Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis 2008;14:374-82.
  44. Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn's disease. Aliment Pharmacol Ther 1991;5(2):115-25.
  45. Brown AC, Roy M. Does evidence exist to include dietary therapy in the treatment of Crohn's disease? Expert Rev Gastroenterol Hepatol 2010;4(2):191-215.
  46. Van Den Bogaerde J, Cahill J, et al. Gut mucosal response to food antigens in Crohn's disease. Aliment Pharmacol Ther 2002;16(11):1903-15.
  47. Lorenz-Meyer H, Bauer P, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease: a randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol. 1996;31:778-85.
  48. Heckers H, Melcher FW, et al. Chemically prepared fats and Crohn disease: a pilot study of the occurrence of trans-fatty acids in the subcutaneous tissue of Crohn patients in comparison with healthy controls as a parameter of long-term fat intake. Z Gastroenterol. 1988;26(5):259-64.
  49. Barclay GR, McKenzie H, et al. The effect of dietary yeast on the activity of stable chronic Crohn's disease. Scand J Gastroenterol 1992;27:196-200.
  50. Bentz S, Hausmann M, et al. Clinical relevance of igg antibodies against food antigens in Crohn’s disease: a double-blind cross-over diet intervention study. Digestion 2010;81:252-64.
  51. Triggs CM, Munday K, et al. Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat Res 2010;690(1-2):123-38.
  52. Tighe MP, Cummings JR, Afzal NA. Nutrition and inflammatory bowel disease: primary or adjuvant therapy. Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):491-6.
  53. Nakajima S, Iijima H, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011;27(10):1023-8.
  54. Vagianos K et al. tion assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007 Jul-Aug;31(4):311-9.
  55. Siffledeen JS, Siminoski K, et al. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol. 2003 Aug;17(8):473-8.
  56. Aghdassi E, Wendland BE, et al. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol. 2003 Feb;98(2):348-53.
  57. Tsai F and Coyle WJ. The microbiome and obesity: is obesity linked to our gut flora? Curr Gastroenterol Rep. 2009 Aug;11(4):307-13.
  58. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Netherlands J Med 2007;65(11):411--18.
  59. Scholz D. The role of nutrition in the etiology of inflammatory bowel disease. Curr Probl Pediatr Adolesc Health Care. 2011 Oct;41(9):248-53.
  60. Axelsson C and Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol. 1977;12(1):89-95.
  61. Belli DC et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988 Mar;94(3):603-10.
  62. Meister D, Bode J, et al. Anti-inflammatory effects of enteral diet components on Crohn's disease-affected tissues in vitro. Dig Liver Dis. 2002 Jun;34(6):430-8.
  63. Teahon K, Smethurst P, et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991 Jul;101(1):84-9.
  64. Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn's disease. Long-term maintenance of remission by personalized food exclusion diets. Dig Dis Sci 1987;32(12 Suppl):100S--7S.
  65. Watanabe O et al. Enteral nutrition decreases hospitalization rate in patients with Crohn's disease. J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S134-7.
  66. Kuroki F, Matsumoto T, et al. Selenium is depleted in Crohn's disease on enteral nutrition. Dig Dis. 2003;21(3):266-70.
  67. Rowan FE, Docherty NG, Coffey JC, O'Connell PR. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br J Surg 2009;96(2):151-8.
  68. Pitcher MCL, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut 1996;39:1-4.
  69. Roediger WEW, Moore J, Babidge W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 1997;42:1571-9.
  70. Kaplan GG, Hubbard J, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010;105(11):2412-9.
  71. Jowett SL, Seal CJ, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004;53(10):1479-84.
  72. Roediger WE. Decreased sulphur aminoacid intake in ulcerative colitis. Lancet 1998;351(9115):1555.
  73. Wright R, Truelove SC. A controlled therapeutic trial of various diets in ulcerative colitis. Br Med J 1965;2:138-41.
  74. Alastair F et al. Nutrition in inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2011 Sep;35(5):571-80. Epub 2011 Aug 8.
  75. Mortimore M and Florin TH. A role for B₁₂ in inflammatory bowel disease patients with suppurative dermatoses? An experience with high dose vitamin B₁₂ therapy. J Crohns Colitis. 2010 Oct;4(4):466-70. Epub 2010 Mar 21.
  76. Campos FG, Waitzberg DL, et al. Pharmacological nutrition in inflammatory bowel diseases. Nutr Hosp. 2003 Mar;18(2):57-64.
  77. Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Feb;17(3):307-20.
  78. de Moreno de Leblanc A et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. SRN Gastroenterol. 2011;2011:892971. Epub 2011 Feb 8.
  79. Lavasani S et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010 Feb 2;5(2):e9009.
  80. Chin J. Intestinal microflora: negotiating health outcomes with the warring community within us. Asia Pac J Clin Nutr. 2004;13(suppl):S24-S25.
  81. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004 May;10(3):286-99.
  82. Furrie E, Macfarlane S, et al. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut. 2004 Jan;53(1):91-8.
  83. Sartor RB. Efficacy of probiotics for the management of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011 Sep;7(9):606-8.
  84. Rogler G. Prebiotics and probiotics in ulcerative colitis: where do we stand? Digestion. 2011;84(2):126-7. Epub 2011 Apr 15.
  85. Ishikawa H et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011;84(2):128-33. Epub 2011 Apr 28.
  86. Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22(8):1199-204.
  87. Karimi O, Peña AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: A pilot study. Drugs Today (Barc) 2005;41(7):453-9.
  88. Azcarate-Peril Ma et al. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G401-24. Epub 2011 Jun 23.
  89. Dinleyici Ec et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther. 2012 Feb 16. [Epub ahead of print]
  90. Thomas S et al. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011 Dec;301(6):G1083-92. Epub 2011 Sep 8.
  91. Garcia Vilela E et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 2008;43(7):842-8.
  92. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 May 14;16(18):2202-22.
  93. Deckelbaum RJ et al. The omega-3 Fatty Acid nutritional landscape: health benefits and sources. J Nutr. 2012 Mar;142(3):587S-91S. Epub 2012 Feb 8.
  94. Iwami D et al. Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Int Immunopharmacol. 2011 Mar;11(3):384-9. Epub 2010 Dec 18.
  95. Almallah YZ et al. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998 May;93(5):804-9.
  96. Hillier K et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32(10):1151-5.
  97. Ross E. The role of marine fish oils in the treatment of ulcerative colitis. Nutr Rev. 1993;51(2):47-9.
  98. Steinhart AH et al. Nutrition in inflammatory bowel disease. Curr Opinion Gastroenterol. 1997;13(2):140-5.
  99. Golias C et al. Physiology and pathophysiology of selectins, integrins, and IgSF cell adhesion molecules focusing on inflammation. A paradigm model on infectious endocarditis. ll Commun Adhes. 2011 Jun;18(3):19-32. Epub 2011 Sep 5.
  100. Ibrahim A et al. Dietary α-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition. 2012 Jan 18. [Epub ahead of print]
  101. Uchiyama K et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010 Oct;16(10):1696-707.
  102. Stenson WF et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med. 1992 Apr 15;116(8):609-14.
  103. Aslan A et al. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol. 1992 Apr;87(4):432-7.
  104. Wiese DM et al. The effects of an oral supplement enriched with fish oil, prebiotics, and antioxidants on nutrition status in Crohn's disease patients. Nutr Clin Pract. 2011 Aug;26(4):463-73.
  105. Hawthorne AB, Daneshmend TK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33(7):922-8.
  106. Belluzzi A, Brignola C, et al. Effect of enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334(24):1557-60.
  107. Simopoulos AP. Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet. 2011;102:10-21. Epub 2011 Aug 5.
  108. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002 Oct;56(8):365-79.
  109. Chambers ES et al. The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep. 2011 Feb;11(1):29-36.
  110. Ooi JH et al. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med. 2012 Feb;33(1):77-82. Epub 2011 Nov 6.
  111. Jahnsen J, Falch JA, et al. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37(2):192-9.
  112. Wang TT, Dabbas B, Laperrier D, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta-2 innate immune pathway defective in Crohn disease. J Biol Chem 2010;285(4):2227-31.
  113. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(7):308-15
  114. Miheller P et al. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol. 2010 Nov 28;16(44):5536-42.
  115. Jorgensen SP, Agnholt J, et al. Clinical trial:Vitamin D3 treatment in Crohn's disease---A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010;32:377-83.
  116. Abitbol V et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther. 2002 May;16(5):919-27.
  117. Almeiner HA, Al Menshawy HH, Maher MM, Al Gamal S. Oxidative stress and inflammatory bowel disease. Front Biosci 2012;E4:1335-44.
  118. Koutroubakis IE, Malliaraki N, et al. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004 Sep;49(9):1433-7.
  119. Kruidenier L, Kuiper I, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003 Sep;201(1):28-36.
  120. Trebble TM, Arden NK, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004 Nov;80(5):1137-44.
  121. Trebble TM, Stroud MA, et al. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial. Br J Nutr. 2005 Aug;94(2):253-61.
  122. Hengstermann S et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr. 2008 Aug;27(4):571-8. Epub 2008 Mar 7.
  123. Taylor RA et al. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev. 2011 Jun;16(2):152-6.
  124. Holt PR et al. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005 Nov;50(11):2191-3.
  125. Hanai H, Iida T, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(12):1502-6.
  126. Gerhardt H, Seifert F, et al. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39:11-7 [in German].
  127. Gupta I, Parihar A, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391–5.
  128. Gupta I, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2:37-43.
  129. Holtmeier W, Zeuzem S, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011;17(2):573-82.
  130. Sengupta K et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011 Aug;354(1-2):189-97. Epub 2011 Apr 11.
  131. Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: A double-blind placebo-controlled study. Phytomedicine 2007;14(2-3):87-95.
  132. Langmead L et al. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004b Mar 1;19(5):521-7.
  133. Langmead L et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004a Apr 1;19(7):739-47.
  134. Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000a;54(6):514-21.
  135. Hinks IJ, Inwards KD, Lloyd B, Clayton B. Reduced concentration of selenium in mild Crohn's disease. J Clin Pathol 1988;41:198-201.
  136. Ojuawo A and Keith L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med. 2002 Sep-Oct;48(9-10):116-9.
  137. Geerling BJ, Badart-Smook A, van Deursen C, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000b;6(2):77-84.
  138. Vieira EL et al. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem. 2011 Jun 8. [Epub ahead of print]
  139. Segain JP, Raingeard de la Bletiere D, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397-403.
  140. Assisi RF; GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008;54(3):231-8.
  141. Di Sabatino A, Morera R, et al. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther 2005;22(9):789-94.
  142. Abd-Allah AR et al. Pro-inflammatory and oxidative stress pathways which compromise sperm motility and survival may be altered by L-carnitine. Oxid Med Cell Longev. 2009 Apr-Jun;2(2):73-81.
  143. Buyse J et al. Dietary L-carnitine supplementation enhances the lipopolysaccharide-induced acute phase protein response in broiler chickens. Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):154-9. Epub 2007 May 3.
  144. Shakeri A et al. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int. 2010 Oct;14(4):498-504.
  145. Yuan Y et al. Protective effects of L-carnitine on intestinal ischemia/reperfusion injury in a rat model. J Clin Med Res. 2011 Apr 4;3(2):78-84
  146. Mikhailova TL et al. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther. 2011 Nov;34(9):1088-97.
  147. Den Hond E, Hiele M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1999;23(1):7-11.
  148. Kruschewski M, Perez-Canto S et al. [Protective effect of glutamine on microcirculation of the intestine in experimental colitis]. Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):229-31.
  149. Sido B, Seel C, Hochlehnert A, et al. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci 2006;51(12):2170-9.
  150. Benjamin J et al. Glutamine and Whey Protein Improve Intestinal Permeability and Morphology in Patients with Crohn's Disease: A Randomized Controlled Trial. Dig Dis Sci. 2011 Oct 26. [Epub ahead of print]
  151. Ockenga J et al. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr. 2005 Nov;59(11):1302-9.
  152. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 2002;47(10):2336-48.
  153. Johe PD, Osterud B. The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. J Pineal Res 2005;39:324–330.
  154. Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis 2009;15:134-40.
  155. Boznanska P, Wichan P, et al. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis. Pol Merkur Lekarski 2007;22(131):369-72 [in Polish].
  156. Chojnacki C, Wisniewska-Jarosinska M, et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 2011;62(3):327-34.
  157. Rakhimova OIu . Use of melatonin in combined treatment for inflammatory bowel diseases. Ter Arkh 2010;82(12):64-8 [in Russian].
  158. Maldonado MD, Calvo JR. Melatonin usage in ulcerative colitis: a case report. J Pineal Res 2008;45(3):339-40.
  159. Haden ST, Glowacki J et al. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000 Jun;66(6):414-8.
  160. Head KA et al. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003 Aug;8(3):247-83.
  161. Andus T, Klebl F, et al. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003 Feb;17(3):409-14.
  162. Straub RH, Scholmerich J, et al. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases: substitutes of adrenal and sex hormones. Z Rheumatol. 2000;59(suppl 2):II/108-18.
  163. Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 2004;99(11):2178-85.
  164. Hou JK et al. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011 Apr;106(4):563-73.
  165. Sakamoto N et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005 Feb;11(2):154-63.
  166. Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn's disease with an unrefined-carbohydrate, fiber-rich diet. Br Med J 1979;ii:764-6.
  167. Hanai H, Kanauchi O, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004;13(5):643-7.
  168. Mitamura T, Sakamoto S et al. The more an ulcerative colitis is repeated, the more the risk of colorectal carcinogenesis is increased in mice. Anticancer Res. 2002 Nov-Dec;22(6C):3955-61.
  169. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-G17.
  170. Phelip JM et al. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Feb;14(2):242-8.
  171. Kim DH et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010 Nov;21(11):1919-30. Epub 2010 Sep 5.
  172. Biasco G et al. Folate and prevention of colorectal cancer in ulcerative colitis. Eur J Cancer Prev. 2005 Aug;14(4):395-8.
  173. Fife J et al. Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Dis. 2011 Feb;13(2):132-7. doi: 10.1111/j.1463-1318.2009.02089.x.
  174. Yakut M et al. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med. 2010 Aug;21(4):320-3. Epub 2010 Jun 8.
  175. Oussalah A et al. ta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther. 2011 Nov;34(10):1173-84. doi: 10.1111/j.1365-2036.2011.04864.x. Epub 2011 Oct 3.
  176. Roblin X, Germain E, et al. Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients [in French]. Rev Med Interne. 2006 Feb;27(2):106-10.
  177. Zezos P, Papaioannou G, et al. Hyperhomocysteinemia in ulcerative colitis is related to folate levels. World J Gastroenterol. 2005 Oct 14;11(38):6038-42.
  178. Mahmood A, Needham J, et al. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2005;17:739-44.
  179. Fernandez-Miranda C, Martinez Prieto M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C-->T and 1298A-->C mutations in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2005 Jul;97(7):497-504.
  180. Srirajaskanthan R, Winter M, et al. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2005 Jul;17(7):697-700.
  181. Papa A, Santoliquido A, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):839-46.
  182. Zintzaras E. Genetic variants of homocysteine/folate metabolism pathway and risk of inflammatory bowel disease: a synopsis and meta-analysis of genetic association studies. Biomarkers. 2010 Feb;15(1):69-79.
  183. Etzel JP et al. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis. 2011 Jan 13. [Epub ahead of print]
  184. Harpavat M, Keljo DJ et al. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol. 2004 Mar;38(3):218-24.
  185. Miheller P, Muzes G, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009;15:1656-1662.
  186. Agrawal M et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011 Dec;9(4):251-7.
  187. Kuwabara A, Tanaka K, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int 2009;20(6):935-42.
  188. Rogler G, Scholmerich J. Extraintestinal manifestations of inflammatory bowel disease [in German]. Med Klin (Munich). 2004 Mar 15;99(3):123-30.
  189. Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003;98(8):1797-801.
  190. Kappelman MD, Horvath-Puho E, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011;60:937–43.
  191. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99(1):97-101.
  192. Sonoda K, Ikeda S, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004;39(10):948-54.
  193. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(6):266-72.
  194. Phang M, Lazarus S, Wood LG, Garg M Diet and thrombosis risk: nutrients for prevention of thrombotic disease. Semin Thromb Hemost 2011;37(3):199-208.